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Abstract
Background: Thrombomodulin-associated coagulopathy (TM-AC) is a rare bleeding 
disorder in which a single reported p.Cys537* variant in the thrombomodulin gene 
THBD causes high plasma thrombomodulin (TM) levels. High TM levels attenuate 
thrombin generation and delay fibrinolysis.
Objectives: To report the characteristics of pedigree with a novel THBD variant caus-
ing TM-AC, and co-inherited deficiency of thrombin-activatable fibrinolysis inhibitor 
(TAFI).
Patients/methods: Identification of pathogenic variants in hemostasis genes by next-
generation sequencing and case recall for deep phenotyping.
Results: Pedigree members with a previously reported THBD variant predicting 
p.Pro496Argfs*10 and chain truncation in TM transmembrane domain had abnor-
mal bleeding and greatly increased plasma TM levels. Affected cases had attenuated 
thrombin generation and delayed fibrinolysis similar to previous reported TM_AC 
cases with THBD p.Cys537*. Coincidentally, some pedigree members also harbored 
a stop-gain variant in CPB2 encoding TAFI. This reduced plasma TAFI levels but was 
asymptomatic. Pedigree members with TM-AC caused by the p.Pro496Argfs*10 
THBD variant and also TAFI deficiency had a partially attenuated delay in fibrinolysis, 
but no change in the defective thrombin generation.
Conclusions: These data extend the reported genetic repertoire of TM-AC and es-
tablish a common molecular pathogenesis arising from high plasma levels of TM ex-
tra-cellular domain. The data further confirm that the delay in fibrinolysis associated 
with TM-AC is directly linked to increased TAFI activation. The combination of the 
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1  | INTRODUC TION
The transmembrane protein thrombomodulin (TM) critically regu-
lates blood coagulation by localizing thrombin to the vascular en-
dothelial surface enabling the activation of several key substrates. 
The targets of the TM-thrombin complex include protein C, which 
after conversion to activated protein C (APC) limits further thrombin 
generation by inactivating coagulation factors Va and VIIIa.1 TM also 
acts as a cofactor in thrombin-mediated activation of the procar-
boxypeptidase thrombin-activatable fibrinolysis inhibitor (TAFI) to 
activated TAFI (TAFIa). TAFIa attenuates the binding of tissue-type 
plasminogen activator (tPA) and plasminogen to fibrin by cleav-
ing carboxyterminal lysines from partially degraded fibrin, thereby 
downregulating fibrinolysis.2
The physiological importance of TM is illustrated by the newly rec-
ognized autosomal dominant bleeding disorder thrombomodulin-as-
sociated coagulopathy (TM-AC), which to date has been associated 
with a single p.Cys537* variant in the thrombomodulin gene THBD.3-6 
This truncation variant results in excessive shedding of large quantities 
of the functionally active TM extracellular domain into plasma. This re-
sults in a significant bleeding diathesis because the high TM levels pro-
mote excessive generation of APC, which suppresses normal thrombin 
generation.3-6 TM-AC is also associated with delayed fibrinolysis that 
can be corrected by inhibition of TAFIa, suggesting that the surplus 
TM in plasma stimulates thrombin-mediated TAFI activation.3
Here we report on a TM-AC pedigree with abnormal bleeding 
associated with a previously unreported THBD variant. We also de-
scribe how some pedigree members also harbor an independently 
inherited loss-of-function rare variant in CPB2 resulting in reduction 
in TAFI levels and TAFIa generation and causing amelioration of the 
delayed fibrinolysis associated with TM-AC.
2  | METHODS
The study pedigree was identified in a systematic inspection of geno-
types in the National Institute for Health Research BioResource–
Rare Diseases, which included a collection of 1472 index cases with 
unexplained bleeding or platelet disorders enrolled between 2012 
and 2016. Informed consent for enrolment and recall for extended 
phenotyping was in accordance with the Declaration of Helsinki (UK 
Research Ethics Committee approval 13/EE/0325). Procedures for 
collection of standardized phenotype terms, whole genome sequenc-
ing, and variant calling were as previously reported.7 DNA sequencing 
for co-segregation analysis was performed using Sanger sequenc-
ing and the ThromboGenomics platform.8 Thrombin generation and 
measurement of soluble TM, TAFI, and TAFIa concentrations were 
performed as described previously.3,9-11 Thrombin generation was 
initiated with 1 pmol/L tissue factor in the presence of 4 µmol/L phos-
pholipids. The clot lysis assays were performed using plasma diluted 
to 30% in 10 mmol/L Tris, 140 mmol/L NaCl, and 0.01% Tween-20 pH 
7.4 and clot formation initiated with 10.6 mmol/L CaCl2 and 0.1 U/mL 
thrombin (Sigma Aldrich) in the presence of 16 mmol/L phospholipids 
(Rossix) and 300 pmol/L tPA (Genentech).
3  | RESULTS/DISCUSSION
3.1 | Detection and annotation of the THBD and 
CPB2 variants
Within the study collection, there was a single index case (II.2, 
Figure 1A) with a previously unreported high-impact THBD variant, 
similar to the variant in previously reported pedigrees with TM-AC.3-
6 This was a monoallelic single nucleotide deletion annotated as 
THBD c.1487delC, p.Pro496Argfs*10 relative to canonical transcript 
ENST00000377103.2. This predicted frameshift from codon 496 
and a stop gain at codon 505 will result in loss of the final 11 resi-
dues of the TM extracellular domain, as well as the transmembrane 
domain and the intracellular domain (UniProtKB P07204; Figure 1B). 
Inspection of the coding regions of genes encoding known interac-
tors of TM within the fibrinolysis pathway revealed that case II.2 
also harbored a monoallelic variant in CPB2, encoding TAFI, anno-
tated as c.340G>A; p.Arg114* relative to the canonical transcript 
rare variants in the pedigree members provides a unique genetic model to develop 
understanding of the thrombin-TM system and its regulation of TAFI.
K E Y W O R D S
bleeding, fibrinolysis, genomics, TAFI (carboxypeptidase B2 [CPB2]/procarboxypeptidase U 
[proCPU]), thrombomodulin
Essentials
• Thrombomodulin-associated coagulopathy (TM-AC) is 
linked to a single reported variant in THBD.
• The complex hemostatic defect comprises reduced 
thrombin generation and delayed fibrinolysis.
• We report a pedigree with a new THBD variant indicat-
ing a common molecular pathogenesis of TM-AC.
• Coinherited TAFI deficiency results in attenuated de-
layed fibrinolysis but not reduced thrombin generation.
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ENST00000181383.10, which was absent in reference datasets.7,12 
This variant predicts premature truncation of the TAFI protein from 
residue 114, before the catalytic domain (residues 115-423),2 thereby 
preventing functional TAFI expression from this allele (Figure 1C). The 
THBD variant p.Pro496Argfs*10 was identified in five further pedi-
gree members (II.3, III.2, III.3, IV.1, and IV.2; Figure 1A). Only case II.3 
also harbored CPB2 p.Arg114*. A single pedigree member (III.4) har-
bored CPB2 p.Arg114* but not THBD p.Pro496Argfs*10 (Figure 1A).
3.2 | Characteristics of the TM-AC cases
The adult cases with THBD p.Pro496Argfs*10 (II.2, II.3, III.2, 
and III.3) all reported bleeding (median International Society on 
Thrombosis and Haemostasis [ISTH] bleeding score 6 versus 0 in the 
unaffected adult pedigree member, Figure 1D), predominantly after 
dental procedures and trauma similar to previously reported TM-AC 
pedigrees,3-6 but also after childbirth. Abnormal bleeding was not 
reported for the two cases in generation IV who were all aged 
14 years or younger at enrolment and who had not undergone inva-
sive dental or surgical procedures. Coinheritance of CPB2 p.Arg114* 
(cases II.2 and II.3) had no discernible effect on the frequency or 
severity of bleeding. Plasma coagulation times, clotting factor levels, 
and platelet function testing in the THBD p.Pro496Argfs*10 cases 
were normal (data not shown). Consistent with previous reports of 
TM-AC, plasma TM levels were increased by at least two orders of 
magnitude in all pedigree members with THBD p.Pro496Argfs*10 
(Figure 1D). Plasma TAFI levels were almost two-fold lower in the 
F I G U R E  1   Genotype and laboratory characteristics of the thrombomodulin-associated coagulopathy cases. A, Pedigree showing the 
index case (→), indicating the genotype of the individuals for both the THBD and CPB2 variants. The black symbols indicate cases with 
abnormal bleeding symptoms. The white symbols indicate pedigree members without bleeding symptoms, and the gray symbols indicate 
pedigree members unavailable for evaluation. V, variant allele; +, wild type allele. B, Schematic diagram of the mature thrombomodulin 
protein showing the position and amino acid sequence impact of the novel p.Pro496Argfs*10 in relation to the previously described variant 
associated with thrombomodulin-associated coagulopathy. EC, extracellular domain; T, transmembrane domain; IC, intracellular domain. C, 
Schematic diagram of the thrombin-activatable fibrinolysis inhibitor protein indicating the position of the novel p.Arg114* variant. SP, signal 
peptide; AP, activation peptide; CP carboxypeptidase domain. D, Clinical and laboratory characteristics of pedigree members showing THBD 
and CPB2 genotypes. Bleeding symptoms were enumerated using the International Society on Thrombosis and Haemostasis (ISTH) bleeding 
assessment tool.16 ETP, endogenous thrombin potential; TM, thrombomodulin; TAFI, thrombin-activatable fibrinolysis inhibitor; PPH, 
post-partum hemorrhage; V, variant allele; +, wild type allele; NT, not tested. *Indicates abnormal dental bleeding despite pro-hemostatic 
measures including antifibrinolytic and plasma treatment. Control ranges are shown in square brackets
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three cases harboring CPB2 p.Arg114* compared to cases without 
this genotype (mean ± standard error of the mean [SEM] 542 ± 81 
versus 1025 ± 113 U/L, Figure 1D), consistent with absent expres-
sion of the CPB2 allele harboring the p.Arg114* variant.
To investigate potential interactions between the THBD and 
CPB2 genotypes, we compared thrombin generation in plasma from 
adult pedigree members and control plasma (National Institute for 
Biological Standards and Control standard plasma) as previously re-
ported.3 The TM-AC cases (II.2, III.2, and III.3) demonstrated a reduc-
tion in endogenous thrombin potential and reduced peak thrombin 
concentration (Figure 1D). The differences in thrombin generation 
between cases and controls were smaller following initiation with 
5 pmol/L tissue factor but the overall trend was the same (data not 
shown). These data with THBD p.Pro496Argfs*10 echo those of 
the previous descriptions of TM-AC associated with the p.Cys537* 
variant and are consistent with increased generation of APC and 
excessive suppression of thrombin generation.3-6 The presence of 
the additional CPB2 p.Arg114* variant in the TM-AC case II.2 had no 
discernible effect on thrombin generation.
3.3 | The CPB2 p.Arg114* variant downregulates 
fibrinolysis
The effect of the THBD and CPB2 variants on tPA-mediated fibrinol-
ysis was analyzed by monitoring the turbidity of plasma samples 
after clot formation with 0.1 U/mL thrombin and calcium. In vitro 
plasma clot lysis was significantly delayed in samples from TM-AC 
cases III.2 and III.3 harboring the THBD variant alone (mean ± SEM 
time to 50% lysis [CLT] 223 ± 5.2 and 221 ± 5.9 minutes respec-
tively versus 85 ± 1.9 minutes in control; P < .0001; Figure 2A, B), 
similar to previously reported cases with TM-AC.3 In the TM-AC 
case II.2, who also harbors the CPB2 p.Arg114* variant, fibrinolysis 
was delayed compared to control plasma, but to a lesser extent than 
the TM-AC cases without CPB2 p.Arg114* (CLT 127 ± 1.6 minutes, 
P < .0001). Clot lysis was enhanced in case III.4 who had the CPB2 
p.Arg114* variant but did not carry the THBD mutation (CLT 66 ± 0.4 
versus 85 ± 1.9 minutes in control, P < .001; Figure 2A, B).
To explore whether the modulatory effect of CPB2 p.Arg114* on 
fibrinolysis was a consequence of a reduction in the TAFI level, TAFIa 
F I G U R E  2   Delayed fibrinolysis in thrombomodulin-associated coagulopathy. A, Representative turbidity curves showing clot lysis in 
platelet-free plasma from controls or thrombomodulin-associated coagulopathy (TM-AC) cases. B, 50% lysis times were calculated from 
triplicate plasma samples using Shiny App for calculating clot lysis times.17 Experiments were performed with and without 25 µg/mL potato 
tuber carboxypeptidase inhibitor (PTCI, Sigma Aldrich) or 65 μg/mL MA-T12D11.11 Data shown represent the mean ± standard error of 
the mean of the turbidity measurements. ***P < .001 ****P < .0001 case versus control in plasma without thrombin-activatable fibrinolysis 
inhibitor (TAFI) inhibitors. Statistical significance was determined by one-way analysis of variance with Bonferroni's post hoc test. C, 
Representative profiles of biphasic activated TAFI (TAFIa) generation during in vitro clot lysis from controls or TM-AC cases. Clot lysis was 
performed as in (A) and simultaneously a second identical experiment was performed where at defined time points samples were collected 
and aprotinin (130 µg/mL) and trifluoroacetate salt (PPACK; 5 µmol/L) were added to stop TAFIa generation, after which the samples were 
placed on ice. Peak 1 (P1) and peak 2 (P2) correspond to thrombin-thrombomodulin-mediated and plasmin-mediated TAFIa generation 
respectively. D, TAFIa activity levels for P1 and P2 of TAFI generation during in vitro clot lysis for all adult pedigree members. Data 
represents mean ± standard deviation (n = 6)
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concentration was measured during in vitro clot lysis. This model en-
ables resolution of two peaks of TAFIa formation, generated first by 
TM/thrombin (P1) and subsequently by plasmin (P2; Figure 2C). In 
the TM-AC cases III.2 and III.3 who had the THBD variant alone, P1 
was dramatically elevated almost 50-fold over controls. In pedigree 
members II.2 and II.3 that harbor both the THBD and CPB2 p.Arg114* 
there was approximately a 50% reduction in P1 in the TAFIa genera-
tion curves compared to those members of the pedigree with THBD 
only (Figure 2C, D). P2 was diminished in all TM-AC cases, reflect-
ing consumption of plasma TAFI in the first peak by excessive TM/
thrombin-dependent activation. Both phases of TAFIa generation 
were significantly reduced in case III.4 with the CPB2 p.Arg114* vari-
ant alone compared to the control, consistent with reduced plasma 
TAFI levels (Figure 2C, D). Pharmacological inhibition of TAFIa ac-
tivity with potato tuber carboxypeptidase inhibitor (PTCI) or direct 
inhibition of thrombin-thrombomodulin mediated TAFI activation 
with the specific antibody MA-T12D11 partially corrected the de-
layed fibrinolysis in the TM-AC cases III.2 and III.3 with the THBD 
variant (Figure 2B). The concentrations of inhibitors included here 
had previously been used to overcome TAFIa activity in plasma.3,13,14 
However, in this study the exceptionally high concentrations of TM 
in the plasma of the case studies precluded the complete correction 
of clot lysis time. Higher concentrations of inhibitor were able to re-
duce levels further (data not shown). In TM-AC case II.2, who also 
harbors CPB2 p.Arg114*, the same concentrations of inhibitor per-
mitted more complete correction of the fibrinolytic abnormalities, 
with clot lysis times similar to those of control plasma (Figure 2B). 
These data are the first to describe a genetic deficiency of TAFI and 
emphasize the key role of TAFI in attenuating fibrinolysis in TM-AC.
4  | CONCLUSION
The pedigree described herein harbors a variant in THBD that marks 
only the second worldwide reported genetic variant to result in 
the rare bleeding disorder TM-AC. The variant identified, THBD 
p.Pro496Argfs*10, predicts protein chain truncation close to the 
transmembrane domain, thereby promoting excessive shedding of 
the TM extracellular domain. The marked elevation in plasma TM at-
tenuates thrombin generation and delays fibrinolysis. This is a similar 
consequence to the THBD p.Cys537* variant associated with all pre-
viously described cases of TM-AC.3-6 The reported results suggest 
a common pathogenic mechanism in both THBD variants in which 
the chain truncation promotes shedding of a functionally active TM 
extracellular domain into plasma.15
Remarkably, some pedigree members also harbor a pathogenic 
variant in CPB2 predicting p.Arg114* in TAFI, resulting in partial 
deficiency of plasma TAFI levels. To our knowledge this is the first 
known case of a genetic deficiency in TAFI to be described in hu-
mans. We show that TAFI deficiency is clinically asymptomatic, but 
that the reduction of procarboxypeptidase activity in plasma ac-
celerates fibrinolysis in vitro. Coinheritance of the CPB2 p.Arg114* 
with THBD p.Pro496Argfs*10 partially ameliorates the delayed 
fibrinolytic profile associated with TM-AC, clearly demonstrating a 
crucial role for TAFI in this laboratory feature of TM-AC. The effect 
of this variant was similar to pharmacological inhibition of TAFIa in 
members of the pedigree with TM-AC. Analysis of this pedigree, in 
which members have highly impactful variants affecting two inter-
acting coagulation pathway genes, enhances our understanding of 
ultra-rare human hemostatic disorders. The different combinations 
of the variants in the pedigree family members is a unique platform 
to allow insights into the regulation of the TM/thrombin system and 
TAFI activation that is highly relevant to a broad range of hemostatic 
disorders and therapies. The asymptomatic nature of genetic deple-
tion of human TAFI underscores the potential to exploit inhibition of 
TAFI pharmacologically without bleeding complications.
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